Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down – What’s Next?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) gapped down before the market opened on Thursday . The stock had previously closed at $23.55, but opened at $22.54. Chugai Pharmaceutical shares last traded at $23.53, with a volume of 22,719 shares.

Chugai Pharmaceutical Trading Down 0.3%

The company has a 50 day moving average price of $22.80 and a 200 day moving average price of $24.47. The company has a market capitalization of $77.27 billion, a P/E ratio of 29.72 and a beta of 0.64.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its earnings results on Friday, October 24th. The company reported $0.23 EPS for the quarter. Chugai Pharmaceutical had a return on equity of 20.80% and a net margin of 33.08%. As a group, sell-side analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 EPS for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.